CN113908235B - Chinese herbal compound preparation for treating diabetic retinopathy and preparation method and application thereof - Google Patents

Chinese herbal compound preparation for treating diabetic retinopathy and preparation method and application thereof Download PDF

Info

Publication number
CN113908235B
CN113908235B CN202111459288.5A CN202111459288A CN113908235B CN 113908235 B CN113908235 B CN 113908235B CN 202111459288 A CN202111459288 A CN 202111459288A CN 113908235 B CN113908235 B CN 113908235B
Authority
CN
China
Prior art keywords
traditional chinese
diabetic retinopathy
root
dendrobium
chinese medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111459288.5A
Other languages
Chinese (zh)
Other versions
CN113908235A (en
Inventor
赵越
周希乔
余江毅
安晓飞
余旭
吴豪
娄妍
周正国
王恒
沈建江
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Provincial Hospital of Chinese Medicine
Original Assignee
Jiangsu Provincial Hospital of Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Provincial Hospital of Chinese Medicine filed Critical Jiangsu Provincial Hospital of Chinese Medicine
Priority to CN202111459288.5A priority Critical patent/CN113908235B/en
Publication of CN113908235A publication Critical patent/CN113908235A/en
Application granted granted Critical
Publication of CN113908235B publication Critical patent/CN113908235B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8984—Dendrobium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a traditional Chinese medicine compound preparation for treating diabetic retinopathy, a preparation method and application thereof. The traditional Chinese medicine compound preparation is prepared from the following traditional Chinese medicines: astragalus root, dried rehmannia root, dendrobium, flower of sunset abelmoschus, tree peony bark, root of red-rooted salvia, pseudo-ginseng powder and buddleja officinalis. The traditional Chinese medicine compound preparation can be used for treating diabetic retinopathy, and has the functions of inhibiting the overexpression of TGF-beta 1 protein, mRNA, VEGF protein and mRNA in diabetic retinopathy lower retina tissues, and promoting the improvement of miR-200b level in diabetic retinopathy lower retina tissues, so that the specific condition of a disease can be accurately matched, and the diagnosis and treatment effects can be improved.

Description

Chinese herbal compound preparation for treating diabetic retinopathy and preparation method and application thereof
Technical Field
The invention relates to a traditional Chinese medicine compound preparation for treating diabetic retinopathy, a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines.
Background
To the inventors' knowledge, diabetic retinopathy (hereinafter DR) is one of the major microvascular complications of diabetes (hereinafter DM), which is known as "diabetes mellitus" in chinese medicine. Recent meta-analysis shows that: the total incidence of DR in the DM population is about 34.6%, DR has become a major cause of vision loss in the middle aged and elderly people worldwide. The pathogenesis of DR is not completely elucidated at present, and active search for effective intervention means has extremely important significance for DR control.
In the latest DR clinical control guidelines established by the american ophthalmology society, metabolic disorders such as blood sugar, blood pressure, blood fat and the like are still strictly controlled as main drug control means. Whereas panretinal photocoagulation, anti-VEGF mab postballoon injection and vitrectomy are optional for use in the presence of severe non-proliferative diabetic retinopathy (hereinafter NPDR) or proliferative diabetic retinopathy (hereinafter PDR) in combination with corresponding indications. Also in the guidelines, it is suggested that patients with Diabetic Macular Edema (DME), severe NPDR and PDR should be promptly referral to ophthalmologists who are experienced in DR clinical management. Therefore, selection of appropriate drugs in the early stages of DR to alleviate and prevent further exacerbation of lesions is an important responsibility of all endocrinologists and general practitioners responsible for DR management.
In regard to the pharmaceutical intervention of DR, besides basic treatments for controlling blood sugar, blood pressure, blood fat, etc., other drugs such as drugs for improving microcirculation, free radical scavengers, antithrombotic drugs, inhibitors of diacylglycerol-protein kinase C, etc. may have a certain therapeutic effect on DR, but their effects are relatively limited, and further intensive researches are required.
Traditional Chinese medicine accumulates a great deal of experience in the development and prevention of DR in long-term clinical practice. The treatment means aiming at DR comprise various modes such as dialectical treatment, stage treatment, special prescription and special medicine, traditional Chinese medicine extract, acupuncture and moxibustion, traditional Chinese medicine ion introduction and the like. Related researches indicate that the traditional Chinese medicine can reduce the apoptosis of periretinal cells and improve the function of endothelial cells by improving oxidative stress and inflammatory states, and can inhibit the proliferation of retinal neovascularization by regulating certain cytokines such as hypoxia inducible factor-1 alpha, insulin growth factor-1, interleukin-6, tumor necrosis factor-alpha and the like so as to achieve the aim of improving DR. However, the research on intervention DR of the traditional Chinese medicine compound preparation is mainly based on clinical observation, the research evidence of animal experiments and related mechanism exploration is relatively less, and the research result is needed to be added.
The invention patent application of application No. CN20061007164.1 and application publication No. CN1857531A discloses a traditional Chinese medicine preparation prescription for treating diabetic retinopathy and a preparation method thereof; the invention patent No. CN201110194682.0 and the patent No. CN102258709B also disclose a Chinese medicinal preparation for treating diabetic retinopathy and a preparation method thereof. The technical schemes are different from the research results related to the invention, and the technical schemes do not have related researches in the aspect of mechanism exploration, so that there is still room for improvement.
Disclosure of Invention
The main purpose of the invention is as follows: overcomes the problems existing in the prior art, provides a traditional Chinese medicine compound preparation for treating diabetic retinopathy, can inhibit the overexpression of TGF-beta 1 protein and mRNA, VEGF protein and mRNA in retina tissues under the pathological changes, and can promote the improvement of miR-200b level in the retina tissues under the pathological changes. Meanwhile, the preparation method and the application of the corresponding Chinese herbal compound preparation are also provided.
The technical scheme for solving the technical problems is as follows:
a Chinese herbal compound preparation for treating diabetic retinopathy is characterized by being prepared from the following Chinese herbal medicines: astragalus root, dried rehmannia root, dendrobium, flower of sunset abelmoschus, tree peony bark, root of red-rooted salvia, pseudo-ginseng powder and buddleja officinalis; the weight ratio of the astragalus, the radix rehmanniae, the dendrobium, the abelmoschus manihot, the cortex moutan, the red sage root, the pseudo-ginseng powder and the buddleja officinalis is 15-30:10-20:10-20:30-60:10-20:15-30:3-6:10-15.
In the traditional Chinese medicine compound preparation: astragalus root, radix astragali, sweet in taste and slightly warm in nature, can tonify qi, promote diuresis and remove food stagnation; radix rehmanniae, sweet in flavor, cold in nature, can nourish yin and promote salivation; dendrobium nobile is sweet in flavor and slightly cold in nature, can nourish yin and promote the production of body fluid, and is a main medicine for tonifying qi and nourishing yin; abelmoschus manihot flower is sweet in flavor and cold in nature, and has the actions of clearing damp and heat; cortex moutan, bitter and pungent in nature and slightly cold in nature, has the effects of cooling blood and activating blood; danshen root has bitter taste and slight cold, and has the effects of removing blood stasis and cooling blood; notoginseng radix, sweet in taste, slightly bitter in nature, warm in nature, has the actions of resolving stasis and stopping bleeding, and the four are mutually combined and are principal drugs for resolving dampness and activating blood; buddleja officinalis is sweet in flavor and slightly cold in nature, and has the actions of clearing heat, nourishing liver and improving vision. All Fang Wenliang are combined with the functions of supplementing and clearing heat, and have the effects of tonifying qi and nourishing yin, eliminating dampness and activating blood.
Experiments prove that for retina tissues under diabetic retinopathy, the traditional Chinese medicine compound preparation can improve pathological changes of retina, improve retinal capillary conditions, inhibit overexpression of TGF-beta 1 protein and mRNA, VEGF protein and mRNA in retina tissues, and promote the increase of miR-200b level in retina tissues.
The further perfected technical scheme of the traditional Chinese medicine compound preparation is as follows:
preferably, the weight ratio of the astragalus, the radix rehmanniae, the dendrobium, the abelmoschus manihot, the cortex moutan, the red sage root, the pseudo-ginseng powder and the butterflybush flower is 15:15:10:30:15:15:3:10.
preferably, the Chinese herbal compound preparation is prepared from the following Chinese herbal medicines: 15-30 g of astragalus membranaceus, 10-20 g of radix rehmanniae, 10-20 g of dendrobium nobile, 30-60 g of flos abelmoschus manihot, 10-20 g of cortex moutan, 15-30 g of radix salviae miltiorrhizae, 3-6 g of pseudo-ginseng powder and 10-15 g of flos buddleiae.
More preferably, the Chinese herbal compound preparation is prepared from the following Chinese herbal medicines: 15g of astragalus, 15g of radix rehmanniae, 10g of dendrobium, 30g of flos abelmoschus manihot, 15g of cortex moutan, 15g of radix salviae miltiorrhizae, 3g of pseudo-ginseng powder and 10g of buddleia officinalis.
By adopting the preferable scheme, the weight ratio of each traditional Chinese medicine can be further optimized.
The invention also provides:
the preparation method of the traditional Chinese medicine compound preparation for treating diabetic retinopathy is characterized in that the traditional Chinese medicine compound preparation is a traditional Chinese medicine compound decoction; the preparation method comprises the following steps:
firstly, taking the astragalus, the dried rehmannia root, the dendrobium, the abelmoschus manihot, the cortex moutan, the red sage root and the butterflybush flower with the prescription amount, soaking the materials in clean water for 30-60 minutes, and then putting the materials into a decocting machine;
step two, adding a preset amount of water into a medicine decocting machine, and decocting for 30-60 minutes; extruding the decoction by using a mechanical extrusion part of a decoction machine;
and thirdly, adding the pseudo-ginseng powder with the prescription amount into the medicinal juice, uniformly mixing, and subpackaging the obtained liquid to obtain the finished product.
Preferably, in the second step, the predetermined amount is 500-600 ml of water corresponding to each dose of the Chinese herbal medicine compound preparation.
The preparation method of the traditional Chinese medicine compound preparation for treating diabetic retinopathy is characterized in that the traditional Chinese medicine compound preparation is a traditional Chinese medicine compound extract; the preparation method comprises the following steps:
the first step, taking the astragalus, the radix rehmanniae, the dendrobium, the flos abelmoschus manihot, the cortex moutan, the red sage root and the butterflybush flower with the prescription amount, and decocting for at least 2 times with water for 1-2 hours each time; mixing decoctions, and filtering to obtain filtrate;
secondly, concentrating the filtrate under reduced pressure at 65-85 ℃ for 3-4 hours to obtain extractum; continuously stirring the extract at 80+/-5 ℃ for 30-40 minutes, adding the pseudo-ginseng powder with the prescription amount, and continuously stirring until the extract is uniformly mixed;
and thirdly, spray drying the obtained mixture to obtain a finished product.
By adopting the preparation method, the Chinese herbal medicine compound decoction or the Chinese herbal medicine compound extract can be prepared for patients to take.
Preferably, in the second step, the stirring time after adding the pseudo-ginseng powder is 5-10 minutes.
The invention also provides:
the application of the traditional Chinese medicine compound preparation in preparing a medicine for treating diabetic retinopathy.
Preferably, the therapeutic effect of the medicament comprises improving a pathological change of the diabetic retinopathy, improving diabetic retinopathy retinal capillary conditions, inhibiting the overexpression of TGF-beta 1 protein and mRNA, VEGF protein and mRNA in diabetic retinopathy retinal tissue, promoting elevated miR-200b levels in diabetic retinopathy retinal tissue.
The traditional Chinese medicine compound preparation can be used for treating diabetic retinopathy, and has the functions of inhibiting the overexpression of TGF-beta 1 protein, mRNA, VEGF protein and mRNA in diabetic retinopathy lower retina tissues, and promoting the improvement of miR-200b level in diabetic retinopathy lower retina tissues, so that the specific condition of a disease can be accurately matched, and the diagnosis and treatment effects can be improved.
Drawings
FIG. 1 is a graph (HE X200) showing comparison of HE staining results of retinal tissues of rats in each group according to the embodiment of the present invention.
FIG. 2 is a graph showing comparison of results of retinal vascular digestion patches (PAS. Times.200) of rats in each group according to the present invention.
FIG. 3 is a comparison of TGF-beta 1 and VEGF protein immunofluorescence in rat retinal tissue from various groups according to an embodiment of the present invention.
FIG. 4 is a graph showing comparison of TGF- β1 and VEGF protein expression in rat retinal tissues of various groups according to the examples of the present invention.
FIG. 5 is a graph showing comparison of TGF-beta 1mRNA, miR-200b and VEGF mRNA expression in rat retinal tissues of each group according to an embodiment of the invention.
Detailed Description
In the research of the project, the inventor firstly confirms that traditional Chinese medicines such as radix rehmanniae, cortex moutan, flos abelmoschus manihot and the like have curative effects on diabetic retinopathy (hereinafter referred to as DR) through the research of known formulas, and provides basis for treating DR by adopting a method of nourishing yin, resolving dampness and promoting blood circulation. Then, based on literature investigation and development, combining the pathogenesis characteristics of DR 'deficiency of both qi and yin, wet stasis and obstruction of collaterals' and the clinical experience of DR diagnosis and treatment in the past, the formulation of the traditional Chinese medicine compound preparation is formulated as follows: astragalus root, dried rehmannia root, dendrobium, flower of sunset abelmoschus, tree peony bark, root of red-rooted salvia, pseudo-ginseng powder and buddleja officinalis. Fumbling experiments were then performed on the doses of the traditional Chinese medicine and the determination was made: the weight ratio of astragalus, radix rehmanniae, dendrobium, flos abelmoschus manihot, cortex moutan, red sage root, pseudo-ginseng powder and butterflybush flower is 15-30:10-20:10-20:30-60:10-20:15-30:3-6:10-15 parts; in the experimental process, after the traditional Chinese medicine compound preparation (decoction) is taken by a patient with DR combined macular edema, the vision is obviously improved and the macular edema is reduced; however, some patients feel dryness-heat after taking the medicine, so that the dosage of the astragalus is adjusted to be reduced to the range, the cortex moutan is adjusted to be increased to the range, and the dryness-heat symptoms of the patients are improved without changing the other patients. Finally, animal and clinical studies were conducted at the above determined dose ratios.
In specific implementation, the traditional Chinese medicine compound preparation for treating diabetic retinopathy is prepared from the following traditional Chinese medicines: astragalus root, dried rehmannia root, dendrobium, flower of sunset abelmoschus, tree peony bark, root of red-rooted salvia, pseudo-ginseng powder and buddleja officinalis; wherein, the weight ratio of astragalus root, dried rehmannia root, dendrobium, abelmoschus manihot, cortex moutan, red sage root, notoginseng powder and butterflybush flower is 15-30:10-20:10-20:30-60:10-20:15-30:3-6:10-15.
The weight ratio is preferably as follows: 15:15:10:30:15:15:3:10.
the dosage composition is preferably: 15-30 g of astragalus membranaceus, 10-20 g of radix rehmanniae, 10-20 g of dendrobium nobile, 30-60 g of flos abelmoschus manihot, 10-20 g of cortex moutan, 15-30 g of radix salviae miltiorrhizae, 3-6 g of pseudo-ginseng powder and 10-15 g of flos buddleiae. Further preferred are: 15g of astragalus, 15g of radix rehmanniae, 10g of dendrobium, 30g of flos abelmoschus manihot, 15g of cortex moutan, 15g of radix salviae miltiorrhizae, 3g of pseudo-ginseng powder and 10g of buddleia officinalis.
Specific examples of dose compositions are as follows:
example 1, astragalus root 15g, dried rehmannia root 15g, dendrobium 10g, flower of Abelmoschus manihot 30g, root bark of tree peony 15g, root of red rooted saliva 15g, notoginseng powder 3g, buddleia flower 10g.
Example 2, astragalus mongholicus 30g, radix rehmanniae 10g, dendrobe 20g, flos abelmoschus manihot 60g, cortex moutan 10g, radix salviae miltiorrhizae 30g, radix notoginseng powder 6g and buddleja officinalis 15g.
Example 3, astragalus root 21g, dried rehmannia root 20g, dendrobium 17g, flower of abelmoschus manihot 44g, root bark of tree peony 20g, root of red rooted saliva 19g, notoginseng powder 5g, buddleia flower 13g.
The Chinese herbal medicine compound preparation of the invention can be Chinese herbal medicine compound decoction, and the specific preparation method is as follows:
firstly, taking the astragalus, the dried rehmannia root, the dendrobium, the abelmoschus manihot, the cortex moutan, the red sage root and the butterflybush flower with the prescription amount, soaking the materials in clean water for 30-60 minutes, and then putting the materials into a decocting machine;
step two, adding a preset amount of water into a medicine decocting machine, and decocting for 30-60 minutes; extruding the decoction by using a mechanical extrusion part of a decoction machine; the preset amount is 500-600 ml of water corresponding to each dose of the Chinese herbal medicine compound preparation;
and thirdly, adding the pseudo-ginseng powder with the prescription amount into the medicinal juice, uniformly mixing, and subpackaging the obtained liquid to obtain the finished product.
The Chinese herbal compound preparation of the invention can also be a Chinese herbal compound extract, and the specific preparation method comprises the following steps:
the first step, taking the astragalus, the radix rehmanniae, the dendrobium, the flos abelmoschus manihot, the cortex moutan, the red sage root and the butterflybush flower with the prescription amount, and decocting for at least 2 times with water for 1-2 hours each time; mixing decoctions, and filtering to obtain filtrate;
secondly, concentrating the filtrate under reduced pressure at 65-85 ℃ for 3-4 hours to obtain extractum; continuously stirring the extract at 80+ -5deg.C for 30-40 min, adding Notoginseng radix powder with prescribed amount, and continuously stirring until mixing (stirring for 5-10 min);
and thirdly, spray drying the obtained mixture to obtain a finished product.
The Chinese herbal compound preparation can be used for preparing medicines for treating diabetic retinopathy. The therapeutic effect of the medicine comprises inhibiting the overexpression of TGF-beta 1 protein and mRNA, VEGF protein and mRNA in retina tissues under diabetic retinopathy, and promoting the increase of miR-200b level in retina tissues under diabetic retinopathy.
The invention is described in further detail below with reference to the accompanying drawings in combination with embodiments. The invention is not limited to the examples given.
Examples
The embodiment is pharmacodynamics data of the traditional Chinese medicine compound preparation.
(1) Experimental materials:
(1) animals: SPF-class healthy male SD (Sprague Dawley) rats, 6 weeks old, have a mass of about 180 g.
(2) A Chinese medicinal compound preparation: prescription dose composition: 15g of astragalus, 15g of radix rehmanniae, 10g of dendrobium, 30g of flos abelmoschus manihot, 15g of cortex moutan, 15g of radix salviae miltiorrhizae, 3g of pseudo-ginseng powder and 10g of buddleja officinalis (namely the example 1). The compound extract of the traditional Chinese medicine (dry granular powder) is prepared according to the method described above by the prescription for standby.
(2) The experimental method comprises the following steps:
of 40 male SD rats, 8 were randomly selected as a normal control group, and 32 other rats were prepared with DR model. DR rats were modeled successfully and randomly assigned to the following 4 groups: DR group, dr+ herbal compound low dose (FFE-L) group, dr+ herbal compound high dose (FFE-H) group, dr+ Calcium Dobesilate (CD) group.
The powder of the traditional Chinese medicine compound extract is respectively prepared by a DR+FFE-L group and a DR+FFE-H group according to a dosage of 1.0g/kg/d and 3.0g/kg/d with a 0.5 percent sodium carboxymethyl cellulose solution, and then the powder is used for lavage of rats. In the DR+CD group, calcium dobesilate was formulated with a 0.5% sodium carboxymethyl cellulose solution at a dose of 135mg/kg/d and the rats were lavaged. The normal control and DR groups were intragastrically given the same amount of 0.5% sodium carboxymethylcellulose solution daily.
After each group had been fed, and filled for 8 weeks, all rats were sacrificed with 3% pentobarbital sodium over anesthesia, the bilateral eyeballs were removed rapidly, the cornea was cut off along the cornel limbus with an ophthalmic scissors, and the anterior segment and vitreous body were removed to make a optic cup. Each group randomly extracts bilateral optic cups of 3 mice, one side was HE stained and the other side was retinal vascular digested with the patch. All the other visual cups separate retinal tissues, and immunofluorescence, PCR and Wb detection of TGF-beta 1 and VEGF, and PCR detection of miR-200b are performed respectively.
(3) Experimental results:
(1) influence of Chinese herbal compound preparation on pathological changes of retina tissue of DR rat
As shown in fig. 1, HE staining results showed: the control group rat retina has normal structure, the cells of the ganglion cell layer are tidy, and the inner core and the outer core cell layer are closely arranged; the arrangement of cells in the cell layer of the rat node in the DR group is more disordered, and the inner core layer and the outer core layer are arranged sparsely and compactly compared with the arrangement of cells in the blank group. Compared with the DR group, the DR+FFE-L group ganglion cell disorder is reduced, and the pathological changes of the DR+FFE-H group and the DR+CD group are obviously further improved.
(2) Influence of Chinese herbal compound preparation on DR rat retinal capillary change
As shown in fig. 2 and table 1, the vascular digestion patch showed: the control group rat retina capillaries are regular in distribution, the diameters of blood vessels are uniform and consistent, the trend is straight, few cell capillaries are visible, and cell ghosts are not visible; microvascular density (14.83.+ -. 2.04)/HPD, E/P ratio (1.03.+ -. 0.12).
The DR group rat retina capillary network is obviously dense, walks in disorder, the pipe diameter is uneven, twists and expands, the pipe wall edge is irregular, a plurality of capillary vessels are twisted and clustered, more cell-free capillary vessels and pericyte ghosts are visible, and endothelial cells are obviously proliferated; the microvascular density (30.33 + -3.83)/HPD and E/P ratios (2.43+ -0.22) were significantly higher than the control (P < 0.001).
The microvascular changes in the DR+FFE-L group were reduced compared to the DR group, and the microvascular density (24.50+ -2.88)/HPD and E/P ratios (1.83+ -0.13) were significantly reduced compared to the DR group (P <0.01, P < 0.001).
The microvascular changes in the DR+FFE-H and DR+CD groups were further improved, and the microvascular density and E/P ratio were significantly reduced (P < 0.001) compared to the DR group.
TABLE 1 comparison of retinal vascular digestion patch microvascular density and E/P ratio for each group
* vs control, P<0.01； ** vs control, P<0.001； # vs DR，P<0.01； ## vs DR，P<0.001
(3) Influence of traditional Chinese medicine compound preparation on expression of TGF-beta 1 and VEGF protein in retina tissue of DR rat
As shown in fig. 3, retinal tissue immunofluorescence shows: the expression of TGF-beta 1 and VEGF in the DR group is obviously enhanced compared with that in the control group, the expression of the DR+FFE-L group is reduced compared with that in the DR group, the expression of the DR+FFE-H group is obviously reduced compared with that in the DR group, and the DR+CD group is most obviously reduced.
As shown in fig. 4, western blot detection of retinal tissue showed that: the expression of TGF-beta 1 and VEGF protein in the DR group is obviously improved (P < 0.01) compared with that in the control group, the expression of VEGF in the DR+FFE-L group is obviously reduced (P < 0.05) compared with that in the DR group, the expression of VEGF in the DR+FFE-H group is obviously reduced (P < 0.05) compared with that in the DR+FFE-L group, and the expression of TGF-beta 1 and VEGF in the DR+CD group are obviously reduced (P < 0.01) compared with that in the DR group.
(4) Influence of traditional Chinese medicine compound preparation on miR-200b and TGF-beta 1 and VEGF mRNA expression in DR rat retina tissue
As shown in fig. 5, the retinal tissue qRT-PCR assay showed that: TGF-beta 1 and VEGF mRNA expression in the DR group are obviously increased (P < 0.01) compared with the control group, and miR-200b expression is obviously reduced (P < 0.01) compared with the control group.
TGF-beta 1 and VEGF mRNA expression in DR+FFE-L group is obviously reduced (P < 0.01) compared with DR group, miR-200b is obviously increased (P < 0.05) compared with DR group.
VEGF mRNA expression was further decreased in the DR+FFE-H group compared to the DR+FFE-L group (P < 0.01), and miR-200b was further increased in the DR+FFE-L group (P < 0.01).
The expression of TGF-beta 1 and VEGF mRNA in the DR+CD group is obviously reduced (P < 0.01) compared with that in the DR group, and the expression of miR-200b is obviously increased (P < 0.01) compared with that in the DR group.
The above examples 2 and 3 also have substantially the same actions and effects as those of the above example 1.
The experimental result proves the effectiveness of the traditional Chinese medicine compound preparation on DR through in vivo experiments of intervention DR model. The anti-aging agent has obvious effect of reducing damage to retina tissues and micro blood vessels (capillaries) of DR rats, can inhibit overexpression of TGF-beta 1 protein and mRNA, VEGF protein and mRNA in the retina tissues of the DR rats, and promotes the improvement of miR-200b level. Therefore, the traditional Chinese medicine compound has a good application prospect in DR prevention and treatment.
In terms of molecular mechanism function:
(1) TGF-beta 1/miR-200b/VEGF pathway activation is an important molecular mechanism for DR to occur.
The high sugar can obviously increase the level and activity of the expression TGF-beta 1 of retina endothelial cells, epithelial cells and the like, and the TGF-beta 1 can inhibit the activity of the miR-200b promoter to reduce the expression level of miR-200 b. miR-200b can specifically bind to VEGF mRNA, thereby inhibiting VEGF protein synthesis. High expression of VEGF in retinal tissue can specifically damage BRB (blood-retinal barrier) resulting in DR. Thus, high sugar causes high expression of TGF-beta 1 in retina to lower miR-200b level, and then VEGF level is increased to damage BRB, and this pathway is regarded as an important molecular mechanism of DR occurrence.
(2) The traditional Chinese medicine compound preparation can obviously inhibit the activation of TGF-beta 1/miR-200b/VEGF channels.
From the foregoing, it can be seen that: the traditional Chinese medicine compound preparation can obviously inhibit the expression of TGF-beta 1, VEGF mRNA and protein in the retina tissue of a DR rat, and can obviously improve the expression of miR-200b, so that the traditional Chinese medicine compound preparation has an obvious inhibition effect on the activation of TGF-beta 1/miR-200b/VEGF channels in the retina tissue of the DR rat. Therefore, the traditional Chinese medicine compound preparation plays a role in treating DR due to the mechanism function.
Calcium dobesilate was used as a positive control in the above examples. Compared with calcium dobesilate, the traditional Chinese medicine compound preparation has the advantages that the curative effect of treating DR is equivalent, and the traditional Chinese medicine compound preparation also has the following advantages:
(1) Good compliance
Traditional Chinese medicine has a long history, good experience and a plurality of patient groups in China, and even internationally enjoys higher popularity. Many patients trust and adhere to the use of traditional Chinese medicine therapy and therefore have good medication compliance.
(2) Multiple dosage forms
The Chinese herbal medicine compound preparation can be prepared into various dosage forms such as paste, pill and the like besides decoction and granules, and can be adapted to different requirements of different patients.
(3) Has unique action mechanism
The traditional Chinese medicine compound preparation plays a role in treating DR by inhibiting TGF-beta 1/miR-200b/VEGF pathway. The mechanism of action of calcium dobesilate has been studied for a long time, and the effect of treating DR is not mainly exerted by the mechanism.
(4) Hygienic and economical advantages
The Chinese herbal medicine has better health and economy advantages when facing the huge medical cost for DR prevention and treatment.
In addition to the embodiments described above, other embodiments of the invention are possible. All technical schemes formed by equivalent substitution or equivalent transformation fall within the protection scope of the invention.

Claims (4)

1. An application of a Chinese medicinal compound decoction in preparing medicine for treating diabetic retinopathy is provided;
the traditional Chinese medicine compound decoction is prepared from the following traditional Chinese medicines: astragalus root, dried rehmannia root, dendrobium, flower of sunset abelmoschus, tree peony bark, root of red-rooted salvia, pseudo-ginseng powder and buddleja officinalis; the weight ratio of the astragalus, the radix rehmanniae, the dendrobium, the abelmoschus manihot, the cortex moutan, the red sage root, the pseudo-ginseng powder and the butterflybush flower is 15:15:10:30:15:15:3:10;
the preparation method of the traditional Chinese medicine compound decoction comprises the following steps:
firstly, taking the astragalus, the dried rehmannia root, the dendrobium, the abelmoschus manihot, the cortex moutan, the red sage root and the butterflybush flower with the prescription amount, soaking the materials in clean water for 30-60 minutes, and then putting the materials into a decocting machine;
step two, adding a preset amount of water into a medicine decocting machine, and decocting for 30-60 minutes; extruding the decoction by using a mechanical extrusion part of a decoction machine;
and thirdly, adding the pseudo-ginseng powder with the prescription amount into the medicinal juice, uniformly mixing, and subpackaging the obtained liquid to obtain the finished product.
2. The use according to claim 1, wherein the predetermined amount of water in the second step is 500-600 ml of water per 15g of astragalus, 15g of radix rehmanniae, 10g of dendrobium, 30g of flos abelmoschus manihot, 15g of cortex moutan, 15g of radix salviae miltiorrhizae, 3g of radix notoginseng powder and 10g of buddleia officinalis.
3. An application of a Chinese medicinal compound extract in preparing medicine for treating diabetic retinopathy;
the traditional Chinese medicine compound extract is prepared from the following traditional Chinese medicines: astragalus root, dried rehmannia root, dendrobium, flower of sunset abelmoschus, tree peony bark, root of red-rooted salvia, pseudo-ginseng powder and buddleja officinalis; the weight ratio of the astragalus, the radix rehmanniae, the dendrobium, the abelmoschus manihot, the cortex moutan, the red sage root, the pseudo-ginseng powder and the butterflybush flower is 15:15:10:30:15:15:3:10;
the preparation method of the traditional Chinese medicine compound extract comprises the following steps:
the first step, taking the astragalus, the radix rehmanniae, the dendrobium, the flos abelmoschus manihot, the cortex moutan, the red sage root and the butterflybush flower with the prescription amount, and decocting for at least 2 times with water for 1-2 hours each time; mixing decoctions, and filtering to obtain filtrate;
secondly, concentrating the filtrate under reduced pressure at 65-85 ℃ for 3-4 hours to obtain extractum; continuously stirring the extract at 80+/-5 ℃ for 30-40 minutes, adding the pseudo-ginseng powder with the prescription amount, and continuously stirring for 5-10 minutes until the extract is uniformly mixed;
and thirdly, spray drying the obtained mixture to obtain a finished product.
4. The use according to any one of claims 1 to 3, wherein the therapeutic effect of the medicament comprises ameliorating a pathological change of the diabetic retinopathy lower retina, ameliorating diabetic retinopathy lower retinal capillary conditions, inhibiting the overexpression of TGF- β1 protein and mRNA, VEGF protein and mRNA in diabetic retinopathy lower retinal tissue, promoting elevated miR-200b levels in diabetic retinopathy lower retinal tissue.
CN202111459288.5A 2021-12-02 2021-12-02 Chinese herbal compound preparation for treating diabetic retinopathy and preparation method and application thereof Active CN113908235B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111459288.5A CN113908235B (en) 2021-12-02 2021-12-02 Chinese herbal compound preparation for treating diabetic retinopathy and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111459288.5A CN113908235B (en) 2021-12-02 2021-12-02 Chinese herbal compound preparation for treating diabetic retinopathy and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN113908235A CN113908235A (en) 2022-01-11
CN113908235B true CN113908235B (en) 2023-07-28

Family

ID=79248914

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111459288.5A Active CN113908235B (en) 2021-12-02 2021-12-02 Chinese herbal compound preparation for treating diabetic retinopathy and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN113908235B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102114189A (en) * 2009-12-31 2011-07-06 谷井文 Chinese medicinal blood glucose reducing tablet for treating diabetes comprising superfine powder
CN109692194A (en) * 2019-02-21 2019-04-30 江苏省中医院 A kind of compound traditional Chinese medicine composite and its preparation method and application for treating diabetic nephropathy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104906251B (en) * 2015-07-10 2017-12-08 江苏省中医院 A kind of Traditional Chinese medicine compound composition with treatment diabetes effect and preparation method and application
CN106581445A (en) * 2016-11-30 2017-04-26 倪强荣 Traditional Chinese medicine prescription for treating diabetic retinopathy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102114189A (en) * 2009-12-31 2011-07-06 谷井文 Chinese medicinal blood glucose reducing tablet for treating diabetes comprising superfine powder
CN109692194A (en) * 2019-02-21 2019-04-30 江苏省中医院 A kind of compound traditional Chinese medicine composite and its preparation method and application for treating diabetic nephropathy

Also Published As

Publication number Publication date
CN113908235A (en) 2022-01-11

Similar Documents

Publication Publication Date Title
CN103656290B (en) Medicine for treating optic atrophy and preparation method of medicine
CN104383296B (en) Traditional Chinese medicine composition for treating xerophthalmia and preparation method thereof
CN102755596A (en) Traditional Chinese medicine for treating phlegm-dampness hyperplasia of mammary glands and preparation method thereof
CN102302740B (en) Preparation method of traditional Chinese medicine used for treating thoracic obstructions caused by yin deficiency of heart and kidney
CN104013919A (en) Traditional Chinese medicine for treating angina pectoris
CN113908235B (en) Chinese herbal compound preparation for treating diabetic retinopathy and preparation method and application thereof
CN103638388B (en) A kind of Chinese medicine composition, preparation and preparation method thereof for the treatment of chloasma
CN102940831A (en) External use effervescent tablet for inhibiting bacteria and curing gynecologic inflammations
CN105412604A (en) Traditional Chinese medicine composition for auxiliary treatment of diabetes and preparation method of traditional Chinese medicine composition
CN103301431B (en) Traditional Chinese medicinal preparation for treating glaucoma and preparation method thereof
CN105079676A (en) Medicine for treating fatty liver and preparing method of medicine
CN104324261A (en) Pharmaceutical composition for treating high blood sugar and preparation method of pharmaceutical composition
CN104491718B (en) Medicine for treating liver-depression and phlegm-stasis type mammary gland hyperplasia and preparation method
CN101199685B (en) Smoked washing medicament for treating chronicity conjunctivitis
CN104958566A (en) Pharmaceutical composition for treating diabetic retinopathy caused by deficiency of both vital energy and yin and preparation method of pharmaceutical composition
CN110624080A (en) Pharmaceutical composition for treating intraocular hemorrhagic diseases with blood heat stasis
CN101322731A (en) Capsule for protecting eye and lowering blood sugar
CN104623546A (en) Pharmaceutical composition for treating proliferation of mammary gland
CN103212030A (en) Traditional Chinese medicine for treating liver depression type hyperplasia of mammary glands and preparation method thereof
CN102940753A (en) Pills for treating glaucoma and preparation method
CN104491476A (en) Medicine for treating yin-deficiency and dryness-heat type diabetic retinopathy and preparation method thereof
CN104645071A (en) Medicine for treating kidney yin deficiency type diabetic retinopathy and preparation method thereof
CN1814130A (en) Medicine preparation for treating piles and its preparing method
CN104324194A (en) Traditional Chinese medicine preparation for treating diabetic nephropathy
CN105288171A (en) Pharmaceutical composition for treating male climacteric syndrome

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant